Cyberonics publishes depression data
This article was originally published in The Gray Sheet
Results from the firm's pivotal and companion studies are published in the journal Biological Psychiatry, aiding the firm's quest to secure reimbursement for VNS Therapy for treatment-resistant depression. The articles represent the same data used to support the firm's PMA submission for the device, including the firm's 235-patient, 21-site pivotal D-02 study. The firm believes that reimbursement will be in place for the therapy by 2007 (1"The Gray Sheet" July 25, 2005, p. 17)...
You may also be interested in...
Cyberonics predicts reimbursement for VNS Therapy for treatment-resistant depression (TRD) will be fully secured by 2007, despite encountering protracted difficulties in gaining FDA approval
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.